Citations

Clear

65 citation(s) found for "Pollack, P".

SERUM PHOSPHATE CHANGES INDUCED BY INJECTIONS OF GLUCOSE INTO DOGS UNDER VARIOUS CONDITIONS
Pollack, Herbert, Millet, Roscoe F., Essex, Hiram E., Mann, Frank C., Bollman, Jesse L.

Mayo Clinic

American Journal of Physiology-Legacy Content | December 24, 2017 | Volume: 110 | Issue: 1 | Pages: 117-122

10.1152/ajplegacy.1934.110.1.117 Get It

COMPOUNDS OF PHOSPHORUS IN THE HEART AND STRIATED MUSCLES OF THE DOG: METHODS OF DETERMINATION AND NORMAL VALUES
Pollack, Herbert, Flock, Eunice V., Bollman, Jesse L.

Mayo Clinic

American Journal of Physiology-Legacy Content | December 24, 2017 | Volume: 110 | Issue: 1 | Pages: 105-116

10.1152/ajplegacy.1934.110.1.105 Get It

CHANGES IN THE PHOSPHORUS COMPOUNDS IN THE PERFUSED HIND LIMB OF THE DOG
Pollack, Herbert, Flock, Eunice V., Mason, Paul, Essex, Hiram E., Bollman, Jesse L.

Mayo Clinic

American Journal of Physiology-Legacy Content | December 24, 2017 | Volume: 110 | Issue: 1 | Pages: 102-104

10.1152/ajplegacy.1934.110.1.102 Get It

Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non–ST‐segment elevation acute coronary syndrome in the PLATO trial
Pollack, Charles V. , Davoudi, Farideh, Diercks, Deborah B. , Lim, Soo Teik , Schulte, Phillip J. , Špinar, Jindřich , Steg, Philippe Gabríel , Storey, Robert F. , Himmelmänn, Anders, Wallentin, Lars , Cannon, Christopher P. , Investigators, on behalf of the PLATO, Becker, Richard C. , James, Stefan Karl , Investigators, on behalf of the PLATO, Storey, Robert F , Steg, P Gabriel

Mayo Clinic

Clinical Cardiology | June 9, 2017 | Volume: 40 | Issue: 6 | Pages: 390-398

10.1002/clc.22733 | PMID 28598510 Get It

AbstractBackgroundGuidelines suggest that “upstream” P2Y12 receptor antagonists should be considered in patients with non–ST‐segment elevation acute coronary syndromes (NSTE‐ACS).HypothesisEarly use of ticagrelor in patients managed with an invasive strategy would be more effective than clopidogrel because of its more rapid onset of action and greater potency.MethodsIn the PLATO trial, 6792 NSTE‐ACS patients were randomized to ticagrelor or clopidogrel (started prior to angiography) and underwent angiography within 72 hours of randomization. We compared efficacy and safety outcomes of ticagrelor vs clopidogrel as a function of “early” (<3h) vs “late” (≥3h) time to angiography. Adjusted Cox proportional hazards models evaluated interaction between randomized treatment and time from randomization to angiography on subsequent outcomes.ResultsOverall, a benefit of ticagrelor vs clopidogrel for cardiovascular death/myocardial infarction/stroke was seen at day 7 (hazard ratio [HR]: 0.67, P = 0.002), day 30 (HR: 0.81, P = 0.042), and 1 year (HR: 0.80, P = 0.0045). There were no significant interactions in the <3h vs ≥3h groups at any timepoint. For major bleeding, overall there was no significant increase (HR: 1.04, 95% confidence interval: 0.85‐1.27); but there was a significant interaction with no difference between ticagrelor and clopidogrel in the early group (HR: 0.79), but higher bleeding risk with ticagrelor in the late angiography group, at 7 days (HR: 1.51, Pint = 0.002). Patterns were similar at 30 days and 1 year.ConclusionsThe benefit of ticagrelor over clopidogrel was consistent in those undergoing early and late angiography, supporting upstream use of ticagrelor.
The Epidemiology and Effect of Sliding Injuries in Major and Minor League Baseball Players
Curriero, Frank C. , Pollack, Keshia M., Mayer, Stephanie W. , Spiker, Andrea M. , D’Angelo, John , Coleman, Struan H. , Camp, Christopher L.

Mayo Clinic

The American Journal of Sports Medicine | May 12, 2017 | Volume: 45 | Issue: 10 | Pages: 2372-2378

10.1177/0363546517704835 | PMID 28499094 Get It

Background: Although sliding occurs frequently in professional baseball, little is known about the epidemiology and effect of injuries that occur during sliding in this population of elite athletes. Purpose: To describe the incidence and characteristics of sliding injuries, determine their effect in terms of time out of play, and identify common injury patterns that may represent appropriate targets for injury prevention programs in the future. Study Design: Descriptive epidemiologic study. Methods: All offensive sliding injuries occurring in Major League Baseball (MLB) and Minor League Baseball (MLB) that resulted in time out of play during a span of 5 seasons (2011-2015) were identified. In addition to player demographics, data extracted included time out of play, location on field where injury occurred, level of play, treatment (surgical vs nonsurgical), direction of slide (head vs feet first), body region injured, and diagnosis. Descriptive statistics were used to describe the distribution of these injuries, and injury rates were calculated per slide. Results: From 2011 to 2015, 1633 injuries occurred as a result of a slide. The total number of days missed per season was 4263. Surgical intervention was required for 134 (8.2%) injuries, and the mean days missed was 66.5 for players treated surgically and 12.3 days for players treated nonoperatively ( P < .001). MLB players were more likely than MiLB players to require surgical intervention (12.3% vs 7.5%, P = .019). Injuries to the hands/fingers represented 25.3% of all injuries and 31.3% of those requiring surgery. Although the majority of injuries occurred at second base (57%), the per-slide injury rate was similar across all bases ( P = .991). The estimated overall frequency of injury in MLB was once per every 336 slides, and the rate of injury for head- and feet-first slides was 1 in 249 and 413 slides, respectively ( P = .119). Conclusion: Injuries occurring while sliding in professional baseball result in a significant amount of time out of play for these elite athletes. Injuries occurring at second base and those occurring to the hands and fingers were most prevalent and may be an appropriate target for future injury prevention programs.
Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.
Michalski, Jeff M. , Pisansky, Thomas M. , Pollack, Alan , Zietman, Anthony L., Stephans, Kevin L. , Gao, Tianming , Stephenson, Andrew J. , Tendulkar, Rahul D. , Agrawal, Shree , Efstathiou, Jason A. , Koontz, Bridget F. , Liauw, Stanley L. , Abramowitz, Matthew C. , Anscher, Mitchell S. , Moghanaki, Drew M. , Den, Robert B. , Lee, W. Robert , Hearn, Jason W.D. , Spratt, Daniel E. , Kattan, Michael W.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 9-9

10.1200/jco.2017.35.6_suppl.9 Get It

9 Background: Early salvage radiation therapy (SRT) following radical prostatectomy (RP) has been shown to reduce biochemical recurrence and distant metastases. We aim to identify factors predictive of prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) from a consortium database from 10 academic institutions. Methods: 2,454 node-negative patients (pts) with detectable post-prostatectomy PSA ( ≥ 0.01 ng/mL) treated with SRT ± neoadjuvant/concurrent androgen deprivation therapy (N/C ADT) were included. Cumulative incidence and Kaplan-Meier methods were used to estimate rates of PCSM and ACM, respectively. Univariate and multivariable analyses (MVA) were performed by competing risks regression and Cox proportional hazards methods for PCSM and ACM. Results: Median follow-up was 5 years from SRT completion and 8 years from date of RP; 24% had pathologic Gleason score (GS) of ≤ 6, 56% GS 7, and 19% GS ≥ 8; 56% extraprostatic extension (EPE), 18% seminal vesicle invasion (SVI), 58% positive surgical margins, and 16% received N/C ADT. Median age at RP and SRT were 62 years (IQR 56-66) and 64 years (59-69), respectively. Median SRT dose was 66 Gy (IQR 65-68) and median pre-SRT PSA was 0.5 ng/mL (IQR 0.3-1.1). MVA performed from SRT completion date demonstrated higher pre-SRT PSA (HR = 2.1), higher GS (GS 7 vs. ≤ 6: HR 2.0; GS ≥ 8 vs. 6: HR 3.3) , SVI (HR 2.5), year of SRT (2000-2004, 1995-1999, 1985-1994 vs. 2005-2012; HR 2.9, HR 2.5, HR 3.6, respectively) were significantly associated with higher PCSM. These same variables were all significantly associated with higher PCSM and ACM rates calculated from both SRT completion date and date of RP. Conclusions: Initiation of early SRT at lower post-operative PSA levels following RP is associated with reduced risk of PCSM and ACM, even when calculated from RP date to account for lead time bias. Other factors significantly associated with PCSM include higher GS, SVI, and earlier year of SRT. [Table: see text]
A biomarker panel associated with distant metastasis in prostate cancer patients treated with radiotherapy as prognostic for DM in a large cohort of prostatectomy patients.
Pollack, Alan , Erho, Nicholas , Noronha, Roshan, Lam, Lucia L.C., Buerki, Christine, Abraham, Sakhi, Karnes, R. Jeffrey , Dicker, Adam P. , Ishkanian, Adrian , Feng, Felix Y. , Stoyanova, Radka , Abraham, Sakhi, Klein, Eric A. , Den, Robert B. , Davicioni, Elai , Dicker, Adam P

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 7_suppl | Pages: 8-8

10.1200/jco.2015.33.7_suppl.8 Get It

8 Background: A number of biomarkers related to cell cycle, angiogenesis or apoptosis have been found to be associated with patient outcome in tissue samples from men treated with first line radiation therapy in RTOG clinical trials using immunohistochemical staining and analysis. In a prior study, four biomarkers (Ki-67, MDM2, p16 and Cox-2) and clinical covariates were included in a model of distant metastasis (DM; Pollack et al, Clin Cancer Res, 2014 [epub ahead of print]) risk. The current study tested the hypothesis that these genes are prognostic for DM in men treated primarily with total prostatectomy using RNA expression profiling. Methods: RNA fromprostatectomy samples from Cleveland Clinic (CC, n=182); Mayo Clinic (MC)-I (n = 545) and II (n=235); Memorial Sloan Kettering Cancer Center (MSKCC, n=131); Erasmus Medical Center (EMC, n=48) and Thomas Jefferson University (TJU, n=130) were profiled using 1.4 million RNA features. A Cox proportional hazards model was built on the MC-I training set to combine the 4 biomarkers into a prognostic risk score (4BMSig). 4BMSig was subsequently evaluated for its prognostic significance separately and in combination with clinical risk factors (biopsy Gleason Score, cT-category and Preop-PSA) for DM. Results: 4BMSig was found to discriminate DM patients significantly for the MC-II (AUC = 0.66, p < 0.001), CCF (AUC = 0.68, p < 0.001), and MSKCC (AUC = 0.71, p = 0.04) datasets, and achieved borderline significance for EMC (AUC = 0.70, p = 0.06). 4BMSig did not discriminate DM in the TJU dataset (only 10 DM events). Pooled multivariable analysis (n = 726) with clinical covariates revealed that 4BMSig is a strong independent prognostic covariate for DM (p < 0.001) and prostate cancer specific mortality (p = 0.005). Conclusions: The four genes identified previously as being associated with DM in radiotherapy patients were incorporated herein into 4BMSig, which was found to have potential as a pretreatment prognostic DM risk assessment tool for men treated with prostatectomy. Further validation would consist of testing 4BMSig from RNA in diagnostic tissue from prostate cancer patients prior to prostatectomy.
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy
Tendulkar, Rahul D. , Agrawal, Shree , Gao, Tianming , Pisansky, Thomas M. , Michalski, Jeff M. , Hamstra, Daniel A. , Feng, Felix Y. , Liauw, Stanley L. , Abramowitz, Matthew C. , Pollack, Alan , Den, Robert B. , Stephans, Kevin L. , Zietman, Anthony L., Lee, W. Robert , Kattan, Michael W. , Stephenson, Andrew J. , Efstathiou, Jason A. , Koontz, Bridget F, Anscher, Mitchell S. , Moghanaki, Drew, Koontz, Bridget F. , Moghanaki, Drew M. , Den, Robert B , Liauw, Stanley L , Abramowitz, Matthew C , Kattan, Michael W

Mayo Clinic

Journal of Clinical Oncology | August 15, 2016 | Volume: 34 | Issue: 30 | Pages: 3648-3654

10.1200/jco.2016.67.9647 | PMID 27528718 Get It

Purpose We aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patients treated in the contemporary era. Methods Individual data from node-negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without concurrent androgen-deprivation therapy (ADT) were obtained from 10 academic institutions. Freedom from biochemical failure (FFBF) and distant metastases (DM) rates were estimated, and predictive nomograms were generated. Results Overall, 2,460 patients with a median follow-up of 5 years were included; 599 patients (24%) had a Gleason score (GS) ≤ 6, 1,387 (56%) had a GS of 7, 244 (10%) had a GS of 8, and 230 (9%) had a GS of 9 to 10. There were 1,370 patients (56%) with extraprostatic extension (EPE), 452 (18%) with seminal vesicle invasion (SVI), 1,434 (58%) with positive surgical margins, and 390 (16%) who received ADT (median, 6 months). The median pre-SRT PSA was 0.5 ng/mL (interquartile range, 0.3 to 1.1). The 5-yr FFBF rate was 56% overall, 71% for those with a pre-SRT PSA level of 0.01 to 0.2 ng/mL (n = 441), 63% for those with a PSA of 0.21 to 0.50 ng/mL (n = 822), 54% for those with a PSA of 0.51 to 1.0 ng/mL (n = 533), 43% for those with a PSA of 1.01 to 2.0 ng/mL (n = 341), and 37% for those with a PSA > 2.0 ng/mL (n = 323); P < .001. On multivariable analysis, pre-SRT PSA, GS, EPE, SVI, surgical margins, ADT use, and SRT dose were associated with FFBF. Pre-SRT PSA, GS, SVI, surgical margins, and ADT use were associated with DM, whereas EPE and SRT dose were not. The nomogram concordance indices were 0.68 (FFBF) and 0.74 (DM). Conclusion Early SRT at low PSA levels after RP is associated with improved FFBF and DM rates. Contemporary nomograms can estimate individual patient outcomes after SRT in the modern era.